Dirk Thye

Form D signer

Dirk Thye

Chief Executive Officer at Quince Therapeutics

Form D signer

Capital raised by Quince Therapeutics

$114.7M+$114.7M latest round

2 Form D filings · first filed May 2026 · South San Francisco, CA

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: —

Career

1 company on file

Quince TherapeuticsBiotech · South San Francisco, CAsince May 2026

Chief Executive Officer

Signatory on Quince Therapeutics's Form D filings · $114.7M raised across 2

Company filings

via EDGAR · Form D for Quince Therapeutics2

DateCompanyFormAmountRole on filing

May 18, 2026Quince TherapeuticsForm D+$114.7MChief Executive Officer

Form DMay 18, 2026 · Quince Therapeutics+$114.7Mas Chief Executive Officer

May 18, 2026Quince TherapeuticsForm D—Chief Executive Officer

Form DMay 18, 2026 · Quince Therapeutics—as Chief Executive Officer

Overview

Last filing May 18, 2026

Dirk Thye is on file as Chief Executive Officer at Quince Therapeutics in South San Francisco, CA. Quince Therapeutics has 2 Form D filings on record, $114.7M raised in total. Dirk Thye appears as a signatory on the company's filings.

LinkedIn profile

Teammates

Quince Therapeutics · 1

June BrayDirector

Products

Quince Therapeutics · 1

eDSPClinical-stage therapeutic

Dexamethasone sodium phosphate encapsulated in a patient's own red blood cells using the AIDE platform, administered as a drug-device combination therapy.